Affimed N.V. (AFMD)
NASDAQ: AFMD · Real-Time Price · USD
0.7000
+0.0063 (0.91%)
May 8, 2025, 4:00 PM - Market closed
Affimed Employees
Affimed had 76 employees as of December 31, 2023. The number of employees decreased by 143 or -65.30% compared to the previous year.
Employees
76
Change (1Y)
-143
Growth (1Y)
-65.30%
Revenue / Employee
$82,725
Profits / Employee
-$1,026,832
Market Cap
11.47M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
AFMD News
- 9 days ago - Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting - GlobeNewsWire
- 15 days ago - Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting - GlobeNewsWire
- 17 days ago - Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement - GlobeNewsWire
- 6 weeks ago - Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting - GlobeNewsWire
- 2 months ago - Affimed to Present at the Leerink Partners Global Healthcare Conference 2025 - GlobeNewsWire
- 5 months ago - Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) - GlobeNewsWire
- 5 months ago - Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer - GlobeNewsWire
- 5 months ago - Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients - GlobeNewsWire